Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23729610 | 0.93 | CES2 (0.49) | CES2GLP1RFAAHTSHRRECQL | |
| SCHEMBL16350546 | 0.91 | CES2 (0.50) | CES2GLP1RFAAHTSHRRECQL | |
| SCHEMBL20230390 | 0.90 | CES2 (0.54) | CES2GLP1RFAAHLPAR1LPAR2 | |
| SCHEMBL19369946 | 0.90 | CES2 (0.54) | CES2GLP1RFAAHLPAR1LPAR2 | |
| SCHEMBL15259277 | 0.90 | CES2 (0.54) | CES2GLP1RFAAHLPAR1LPAR2 | |
| SCHEMBL15107494 | 0.90 | CES2 (0.54) | CES2GLP1RFAAHLPAR1LPAR2 | |
| SCHEMBL12807256 | 0.90 | CES2 (0.46) | CES2GLP1RFAAHTSHRRECQL | |
| SCHEMBL15259279 | 0.90 | CES2 (0.46) | CES2GLP1RFAAHTSHRRECQL | |
| SCHEMBL13226771 | 0.90 | CES2 (0.46) | CES2GLP1RFAAHTSHRRECQL | |
| SCHEMBL26020180 | 0.88 | CES2 (0.54) | CES2GLP1RFAAHLPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108102-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | CES2 4581/4885GLP1R 1/4885FAAH 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.